64 results about "Attention deficit hyperactivity disorder" patented technology

The invention discloses an attention deficit hyperactivity disorder recognition system and recognition method, and belongs to the technical field of attention deficit hyperactivity disorder. The data processing module is used for carrying out preprocessing and feature extraction on the acquired electroencephalogram data; a multi-source feature fusion mechanism is firstly used for the extracted original feature data, and then a data enhancement strategy is applied; a multi-source fusion feedback regulation network model is constructed, wherein the model is of a CNN-GRU parallel modeling structure; the training module is used for inputting the enhanced data into a model for training, key hyper-parameters are dynamically adjusted by a performance feedback adjusting mechanism in the training process, and the performance feedback adjusting mechanism is used for dynamically adjusting key training parameters according to the performance of the verification set; and the classification module is used for classifying to-be-detected samples through the trained multi-source fusion feedback regulation network model and outputting a final recognition result. The ADHD electroencephalogram recognition method effectively improves the accuracy, robustness and generalization performance of ADHD electroencephalogram recognition.

The invention discloses a method and device for distinguishing different subtypes of attention deficit hyperactivity disorder, and the method comprises the steps: setting visual stimulation information and auditory stimulation information, the visual stimulation information comprises visual letter information and visual square position information, and the auditory stimulation information comprises auditory letter pronunciation information and auditory digital pronunciation information; generating a stimulation strategy according to the visual stimulation information and the auditory stimulation information; performing visual and auditory stimulation processing according to the stimulation strategy to obtain a correct rate, average correct response time and a comprehensive score; and according to the correct rate, the average correct reaction time and the comprehensive score, carrying out attention deficit hyperactivity disorder subtype distinguishing treatment to obtain a subtype distinguishing result. According to the method, different subtypes of attention deficit hyperactivity disorder are distinguished, and the accuracy and efficiency are improved. The method can be widely applied to the technical field of behavioral data analysis.

The invention relates to the technical field of attention deficit hyperactivity disorder detection, and discloses a device for detecting cognitive and developmental conditions of children with hyperactivity disorder, which comprises a handle, a head-mounted device, a bracelet, a hierarchical adaptive algorithm module, a multi-dimensional execution module and a data fusion and analysis module, a multi-mode sensing module is arranged in each of the handle, the head-mounted device and the bracelet; a motion capture unit, a high-sensitivity key array, a tactile feedback module and a wireless transmission module are integrated in the handle, and a wireless electroencephalogram acquisition module, a miniature near infrared spectrum module and an eye movement tracking module are integrated in the head-mounted device. According to the invention, through deep fusion of a multi-dimensional cognitive evaluation system and gamepad hardware, the device not only breaks through the limitation of the traditional neuropsychological test in methodology, but also realizes refined capture of ADHD heterogeneity characteristics in the technical level, and provides a hardware basis for establishing an objective and quantitative diagnostic tool with high ecological efficiency.

An apparatus and a method for controlling a pharmaceutical mixer of a medication for Attention Deficit Hyperactivity Disorder (ADHD) based on an assessment of a mental health state of an adolescent. The method comprises: collecting physical information of a user; verifying survey questions regarding mental health depending on the physical information and real-time brain activity data; forming additional survey questions after having verified the answers and calculating a prediction rate of an appearance of symptoms of a mental illness by using AI models; dynamically selecting the most suitable AI model for mental health assessment; verifying a set of survey questions including a plurality of sub-questions depending on the calculated prediction rate; and; outputting result data by adjusting the prediction rate; and transmitting a control signal to the pharmaceutical mixer for the ADHD medicine based on the assessment of the mental health state.

The invention relates to the field of medical image analysis and neuropsychiatric disease diagnosis, and particularly discloses a brain network typing diagnosis system and method for attention deficit hyperactivity disorder. Comprising a data acquisition and preprocessing module, a topological feature extraction module, a supervised manifold learning module, a network reconstruction and diagnosis module, a parameter optimization module and a result verification module, continuous homology analysis is performed on a brain region function connection matrix based on an algebraic topology theory, and a brain region topological feature matrix is generated; utilizing supervised manifold learning to map the brain region topological feature matrix to a Riemannian manifold, and calculating a brain region importance weight map based on ADHD phenotypic features as supervised signals; according to the method, the brain network is subjected to subtype specific reconstruction through the curvature flow theory of Riemannian geometry, the topological difference between different subtypes is calculated, accurate typing diagnosis of ADHD is achieved, and the diagnosis accuracy is improved by 15%-20%.

The present invention belongs to the field of microorganisms, and more specifically, the present invention relates to Lactobacillus sanfranciscous ( Lactobacillus_ sanfranciscensis The present invention relates to the use of a microbial agent in the prevention, diagnosis and / or treatment of attention deficit hyperactivity disorder (ADHD), and a microbial preparation for the prevention and / or treatment of ADHD. This provides further evidence for the correlation between the gut microbiota and ADHD, and also provides new candidates for the treatment of ADHD.

The invention discloses an attention deficit hyperactivity disorder preliminary screening method and system based on surface information time sequence characteristics, and belongs to the technical field of neural networks, and the method comprises the steps: obtaining and preprocessing eye movement data and surface table data, and generating eye movement characteristics and surface table characteristics; processing the eye movement features and the surface features to generate a first hyperactivity classification result; performing feature extraction and fusion processing on the eye movement data and the surface table data to generate a plurality of fusion features; obtaining a rank regularization loss function according to the plurality of fusion features; training the tested-level model based on the rank regularization loss function and a preset tested-level cross entropy loss function to obtain a target tested-level model; and processing the fusion features according to the target subject-level model to generate a second hyperactivity classification result. According to the method, eye movement and surface data are captured in real time, efficient and accurate hyperactivity screening is achieved through the multi-modal fusion algorithm, and the screening efficiency and accuracy are remarkably improved.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

The present invention discloses a method and system for initial screening of attention deficit hyperactivity disorder (ADHD) based on temporal features of surface information, belonging to the field of neural network technology. The method comprises: acquiring and preprocessing eye movement data and facial surface data to generate eye movement features and facial surface features; processing the eye movement features and facial surface features to generate a first ADHD classification result; performing feature extraction and fusion processing on the eye movement data and facial surface data to generate multiple fused features; obtaining a rank regularization loss function based on the multiple fused features; training a subject-level model based on the rank regularization loss function and a preset subject-level cross-entropy loss function to obtain a target subject-level model; and processing the fused features based on the target subject-level model to generate a second ADHD classification result. The present invention achieves efficient and accurate ADHD screening by capturing eye movement and facial surface data in real time and utilizing a multimodal fusion algorithm, significantly improving screening efficiency and accuracy.

Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof are provided. Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction.

Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Protocadherin 19 (PCDH19) RNA in a cell or subject, and in certain instances reducing the amount of PCDH19 protein in a cell or subject. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodevelopmental disease or disorder. Such neurodevelopmental diseases or disorders include PCDH19 Epilepsy. Such symptoms or hallmarks include seizures, cognitive impairment, intellectual disabilities, autism spectrum disorder, behavioral problems, aggression, anxiety, obsessive-compulsive disorder, hyperactivity, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).

Disclosed are compounds of formula (I) wherein G1 is as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4) for use in the treatment of e.g. a neurodegenerative disorder, a movement disorder, or a brain disorder, such as e.g. Parkinson's disease, drug-induced Parkinsonism, dystonia, Tourette's syndrome, dyskinesias, schizophrenia, cognitive deficits associated with schizophrenia, excessive daytime sleepiness, attention deficit hyperactivity disorder (ADHD), Huntington's disease, chorea, cerebral palsy, and progressive supranuclear palsy. An exemplary compound is e.g. (2,5-difluoro-4-(6-(((3aR,5s,6aS)-2-((tetrahydro-2H-pyran-4-yl)methyl)octahydrocyclopenta[c]pyrrol-5-yl)amino)pyridazin-3-yl)phenyl)(imino)(methyl)-λ6-sulfanone (e.g. example 12; compound no. 7) Pharmacological data on the activity of the compounds in an mAChR M4 cell-based assay are provided (e.g. table 2).TABLE 2Human M4Cpd. No.IC50 (nM)Emin (%)*113.44239.62318.5345846575.4361883746.0385607918.43101.821186.231243.42138.63*% ACh maximum at 30 μM.

The present invention relates to a system and method for real-time screening of Attention Deficit Hyperactivity Disorder using electroencephalographic signals processed through a GPU-accelerated time-frequency inference architecture. The invention enables continuous acquisition of multi-channel electroencephalographic data, adaptive preprocessing for artifact suppression and signal stabilization, and parallel execution of time-frequency transformations to extract neurologically relevant features in real time. Extracted features are analyzed using an inference process configured to identify neurological patterns associated with Attention Deficit Hyperactivity Disorder, while continuous validation of signal quality and temporal consistency ensures diagnostic reliability. The system dynamically adapts analytical parameters based on evolving signal characteristics and regulates computational workload to achieve energy-efficient operation during prolonged monitoring. The invention provides a technically integrated, machine-implemented screening solution capable of delivering reliable, real-time neurological assessment suitable for clinical environments.

The present invention relates to an improved method for the preparation of optically pure (S)-biloxazine or a salt thereof. The (S)-biloxazine prepared according to the preparation method of the present invention can be selectively administered to prevent or treat attention deficit hyperactivity disorder (ADHD). Accordingly, the dosage of a drug can be reduced by half or more, and side effects can be reduced.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 1-((1H-pyrazol-4-yl)methyl)-3-(phenyl)-1,3-dihydro-2H-imidazol-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 100 to page 143; examples 1 to 167; test examples 1 and 2; tables 1 to 4).

Contemplated test kits, diagnostic apparatus and methods using same for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Kits and diagnostic apparatus include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

The application discloses a game adjusting method and device and a storage medium, and relates to the technical field of games, and can improve the exercise efficiency of attention deficit hyperactivity disorder.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

The present invention discloses a method for identifying attention deficit hyperactivity disorder (ADHD) using functional near-infrared spectroscopy (fNIRS) and infrared thermography. The method includes separately collecting near-infrared blood oxygenation data of a subject in a resting state and a task state, as well as infrared thermograms of the head and neck regions. Then, the near-infrared blood oxygenation data is preprocessed and feature-extracted. After normalization and principal component analysis (PCA) for feature dimensionality reduction, it is input into a functional near-infrared blood oxygenation data anomaly detection model for detection, and a blood oxygen classification result is output. The infrared thermogram is input into an infrared thermogram anomaly detection model to output an infrared thermogram classification result. Finally, the blood oxygen classification result and the infrared thermogram classification result are summarized. The present invention utilizes the non-invasive, non-intrusive, and wide applicability characteristics of functional near-infrared spectroscopy and infrared thermography examinations to quickly and accurately achieve the purpose of classifying abnormal near-infrared blood oxygenation data and abnormal regions in infrared thermograms. Combining the two detection methods can make the detection results more comprehensive, reliable, and persuasive.

The attention deficit hyperactivity disorder alert device includes a controller, non-transitory computer readable memory in communication with the controller, a user interface in communication with the controller, and a display in communication with the controller. The controller is configured to save a plurality of tasks in the non-transitory computer readable memory, assign priority levels to each of the tasks, and assign an alert frequency to each of the tasks. The controller is further configured to display each of the tasks to a user on the display, such that each of the tasks is displayed in a unique color representative of the priority level assigned thereto. The controller is further configured to deliver an alert for each of the tasks to the user, where the alert for each of the tasks is repeated at the alert frequency assigned thereto.

The present technology relates to sensory apparatuses that are useful for individuals who need assistance with neurodevelopmental conditions such as autism spectrum disorder (ASD), sensory processing disorder (SPD), attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD). Such apparatuses can include a top cover connected to or integral with a top base plate, and a bottom cover connected to or integral with a bottom base plate, about which projections or wings having different visual or tactile properties, such as different textures, are rotatably attached. The present technology is also directed to systems and methods for the management of a neurodevelopmental condition.

Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

The present invention provides for an oral solution that includes atomoxetine, or pharmaceutically acceptable salt thereof, methods of manufacturing the oral solution, and methods of treating attention deficit hyperactivity disorder (ADHD) in a human subject that include orally administering the oral solution to a human subject in need thereof.

The invention provides an image processing method and device, equipment, a storage medium and a program product. The method comprises the following steps: acquiring a first text image which is handwritten by a detected object and contains continuous characters; removing background information in the first text image to obtain a second text image; the background information comprises grids or transverse lines; segmenting continuous characters in the second text image to obtain at least two target single character images; performing feature extraction on each target single character image to obtain single character image features; the single-character image features are used for determining whether the detected object has attention deficit hyperactivity disorder (ADHD) or not. The accuracy and comprehensiveness of the result of screening whether the detected object has ADHD or not can be improved.

The invention discloses a traditional Chinese medicine preparation for treating twitch and hyperactivity, and relates to the technical field of traditional Chinese medicine preparations. Atractylodes macrocephala koidz and astragalus membranaceus are used as monarch drugs to strengthen the spleen and stomach, hyacinth beans and coix seeds are used for removing dampness, lotus seed kernels are used for dredging the heart, massa medicata fermentata fujianensis and malt are used for promoting digestion and appetizing, notopterygium roots and radix saposhnikoviae are used as assistants for dredging the upper part, melia toosendan is used for dredging the lower part, oysters and radix paeoniae alba are used for astringing and stabilizing the astringency and regulating the liver to strengthen yin and yang, and all the drugs are used together to achieve the effects of tonifying the spleen, soothing the liver, soothing the nerves and tranquilizing and tranquilizing. The traditional Chinese medicine composition is used for treating attention deficit hyperactivity disorder, tourette syndrome and other diseases caused by spleen deficiency and liver hyperactivity, and the symptoms include hyperactivity, tourette, inattention, impulsive mood, unstable mood and the like.

The present invention belongs to the field of microorganisms, and more particularly, the present invention relates to the use of Lactobacillus sanfranciscensis in the prevention, diagnosis and / or treatment of attention deficit hyperactivity disorder, and a microbial preparation for the prevention and / or treatment of attention deficit hyperactivity disorder. Therefore, a further evidence is provided for the correlation between the intestinal microbiota and the ADHD, and a new candidate is also provided for the treatment of the ADHD.

The present disclosure belongs to the technical field of drug preparation, in particular to a composition and a soft capsule for treating attention deficit hyperactivity disorder (ADHD) in children, and their preparation method and use. In the present disclosure, phosphatidylserine is used as the core active ingredients. On this basis, ginkgo leaves extract and red ginseng extract are selected as supplementary active ingredients.

A system for assessing an ADHD status of a subject comprising:(a) receiving circuitry configured to receive a measurement signal including measurements of a plurality of nasal respirations from a sensor configured to sense a nasal respiration of a subject;(b) optional determining circuitry configured to determine values of one or more nasal respiration parameter from said measurement signal;(c) evaluation circuitry configured to evaluate said subject, based on said values of one or more respiration parameter to provide an indication of ADHD status of said subject.

This invention discloses a system and method for identifying Attention Deficit Hyperactivity Disorder (ADHD), belonging to the technical field of ADHD. The system includes: a data processing module for preprocessing and feature extraction of acquired EEG data; a multi-source feature fusion mechanism followed by data augmentation strategies for the extracted raw feature data; a multi-source fusion feedback regulation network model, employing a CNN-GRU parallel modeling structure; a training module for training the model using augmented data, dynamically adjusting key hyperparameters based on performance feedback on the validation set; and a classification module for classifying test samples using the trained multi-source fusion feedback regulation network model and outputting the final identification result. This invention effectively improves the accuracy, robustness, and generalization performance of ADHD EEG identification.

The invention provides an attention deficit hyperactivity disorder (ADHD) evaluation system and method based on deep learning. The system is composed of a data acquisition module, a deep learning module, an evaluation module, a result output module, a feedback adjustment module and a storage module. Multi-modal data such as high-resolution videos, high-quality audios and physiological signals are collected and processed through a multi-stream fusion convolutional neural network. According to the system, CNN, LSTM and an attention mechanism are creatively fused, and effective analysis and adaptive weight adjustment of multi-modal data are realized. And the evaluation module performs multi-dimensional evaluation by adopting a hierarchical strategy and a dynamic time window technology, and the result is presented in a visual mode. The system has continuous learning ability, performance is continuously optimized through a feedback mechanism, and data security is ensured by adopting distributed storage. The method improves the objectivity, accuracy and efficiency of ADHD evaluation, and is suitable for medical institutions, families and school environments.